Concert Pharma’s Adjunctive Schizophrenia Treatment, CTP-692, Fails to Meet Phase 2 Endpoints
Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did […]
Aptinyx Reports NYX-783 Significantly Improved PTSD Symptoms in Phase 2 Trial
Aptinyx reported positive results from a phase 2 trial evaluating NYX-783 versus placebo in patients with post-traumatic stress disorder (PTSD). […]
Sage Therapeutics Announces Positive Interim, Topline Data from Open-Label SHORELINE Study of Zuranolone in Patients with MDD
Sage Therapeutics announced interim, topline results from a July data cut of the ongoing Phase 3 open-label SHORELINE Study. This […]
Lundbeck Discontinues Phase 2 Study of Lu AF11167 in Patients with Schizophrenia
Lundbeck announced a decision to discontinue a phase II proof of concept clinical study of Lu AF11167 in patients with schizophrenia who are […]
ACADIA Reports Phase 3 CLARITY Study of Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder Fails to Reach Primary Endpoint
ACADIA Pharmaceuticals announced top-line results from its Phase 3 CLARITY study which combined two identical studies evaluating the efficacy, safety […]
BioXcel Therapeutics Meets All Endpoints in Two Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
BioXcel Therapeutics announced that BXCL501, a proprietary sublingual thin film of dexmedetomidine, met the primary and secondary endpoints in the […]
Biohaven Releases Positive Data from Phase 2/3 Study of Troriluzole in the Treatment of Obsessive-Compulsive Disorder (OCD)
Biohaven Pharmaceuticals announced positive topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder (OCD). […]
Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression
Axsome Therapeutics announced top-line results from the phase 3 STRIDE-1 trial evaluating AXS-05 versus active comparator bupropion for treatment of […]
Journal of Clinical Psychiatry Publishes Data from Alkermes Phase 3 ENLIGHTEN-1 Study of ALKS 3831 for Schizophrenia
Alkermes announced that the peer-reviewed publication, Journal of Clinical Psychiatry, has published data from the phase 3 ENLIGHTEN-1 clinical trial […]
FDA Approves Expanded Access Application for MDMA-Assisted Psychotherapy in PTSD Patients
The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the U.S. Food and Drug Administration (FDA) has agreed to […]
